Raal, Frederick J.
Alsheikh-Ali, Alawi A.
Omar, Mohamed I.
Rashed, Wafa
Hamoui, Omar
Kane, Abdoul
Alami, Mohamed
Abreu, Paula
Mashhoud, Walid M.
Funding for this research was provided by:
Pfizer
Article History
Received: 25 September 2017
Accepted: 24 January 2018
First Online: 12 February 2018
Ethics approval and consent to participate
: Ethics approval was obtained from all participating centers and appropriate regulatory bodies in each country. All patients provided informed consent.
: Frederick J. Raal has received research grants, honoraria, or consulting fees for professional input and/or delivered lectures from AstraZeneca, Pfizer, Merck, Sanofi, Regeneron, and Amgen. Alawi A. Alsheikh-Ali declares no conflict of interest. Mohamed I. Omar is a full-time employee of Pfizer. Wafa Rashed declares no conflict of interest. Omar Hamoui is a member of advisory boards, and has received speaking honoraria, from Pfizer, AstraZeneca, Boehringer Ingelheim, Novartis, Servier, Eli Lilly, Takeda, Merck Sharpe & Dohme, and Menirini. Abdoul Kane has received research, honoraria, or consulting fees for professional input and/or delivered lectures from Servier, Pfizer, Merck, and Sanofi. Mohamed Alami declares no conflict of interest. Paula Abreu and Walid M. Mashhoud are full-time employees of Pfizer.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.